We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale ofHemaCare Corporation (“HemaCare” or the “Company”) (OTCMKTS: HEMA) to Charles River Laboratories International, Inc. (“Charles River”) (NYSE: CRL). Under the terms of the agreement, proposed purchase price equates to $25.40 per HemaCare share.
The HemaCare merger investigation concerns whether the Board of HemaCare breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction and whether Charles River is underpaying for HemaCare shares, thus unlawfully harming HemaCare shareholders.
To receive more information, please fill out the form.